Tag: UDCA

Primary Biliary Cholangitis Treatment in 2025: What Works, What Doesn’t, and What’s Next

In 2025, PBC treatment has shifted dramatically with the withdrawal of Ocaliva and the approval of seladelpar and elafibranor. Learn how UDCA remains first-line, why new drugs work better, and what patients should know now.